Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

Dr Evan Alley - University of Pennsylvania, Philadelphia, USA

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma ( Dr Evan Alley - University of Pennsylvania, Philadelphia, USA )

Chk1 inhibition combined with standard dose gemcitabine may be safe and...

Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective ( Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA )

Investigational PD-L1–targeted immunotherapy safe for patients with triple...

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK

BRAF 'behind the scenes' in melanoma: A scientific story of discovery ( Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK )

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for...

Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice ( Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium )

Targeting CDK pathways in cancer treatment

Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA

Targeting CDK pathways in cancer treatment ( Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA )

DNA repair inhibitors to overcome drug resistance

Dr Ruth Plummer - Newcastle University, Newcastle, UK

DNA repair inhibitors to overcome drug resistance ( Dr Ruth Plummer - Newcastle University, Newcastle, UK )

Refining the role of PARP inhibitors in targeted anticancer therapy

Prof Yves Pommier - National Cancer Institute, Bethesda, USA

Refining the role of PARP inhibitors in targeted anticancer therapy ( Prof Yves Pommier - National Cancer Institute, Bethesda, USA )

Developments in immunotherapy

Prof Lillian Siu - University Health Network, Toronto, Canada

Developments in immunotherapy ( Prof Lillian Siu - University Health Network, Toronto, Canada )

Discovering selective anticancer drugs: succeeding slowly is better than...

Professor Hilary Calvert - UCL Cancer Institute, London, UK

Discovering selective anticancer drugs: succeeding slowly is better than failing fast ( Professor Hilary Calvert - UCL Cancer Institute, London, UK )

Putting adoptive T cell therapy on the path to regulatory approval

Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Putting adoptive T cell therapy on the path to regulatory approval ( Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Using Hsp90 inhibitors in the clinic: what have we learned?

Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom

Using Hsp90 inhibitors in the clinic: what have we learned? ( Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom )

More from ecancer